Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT

Sung E. Choi, Ting Fu, Sunmi Seok, Dong Hyun Kim, Eunkyung Yu, Kwan Woo Lee, Yup Kang, Xiaoling Li, Byron Kemper, Jongsook K. Kemper

Research output: Contribution to journalArticle

Abstract

SIRT1 is an NAD+-dependent deacetylase that is implicated in prevention of many age-related diseases including metabolic disorders. As SIRT1 deacetylase activity is dependent on NAD+ levels and the development of compounds that directly activate SIRT1 has been controversial, indirectly activating SIRT1 through enhancing NAD+ bioavailability has received increasing attention. NAD+ levels are reduced in obesity and the aged, but the underlying mechanisms remain unclear. We recently showed that hepatic microRNA-34a (miR-34a), which is elevated in obesity, directly targets and decreases SIRT1 expression. Here, we further show that miR-34a reduces NAD+ levels and SIRT1 activity by targeting NAMPT, the rate-limiting enzyme for NAD+ biosynthesis. A functional binding site for miR-34a is present in the 3′ UTR of NAMPT mRNA. Hepatic overexpression of miR-34a reduced NAMPT/NAD+ levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC-1α, SREBP-1c, FXR, and NF-κB, and resulted in obesity-mimetic outcomes. The decreased NAMPT/NAD+ levels were independent of miR-34a effects on SIRT1 levels as they were also observed in SIRT1 liver-specific knockout mice. Further, the miR-34a-mediated decreases were reversed by treatment with the NAD+ intermediate, nicotinamide mononucleotide. Conversely, antagonism of miR-34a in diet-induced obese mice restored NAMPT/NAD+ levels and alleviated steatosis, inflammation, and glucose intolerance. Anti-miR-34a-mediated increases in NAD+ levels were attenuated when NAMPT was downregulated. Our findings reveal a novel function of miR-34a in reducing both SIRT1 expression and activity in obesity. The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)1062-1072
Number of pages11
JournalAging Cell
Volume12
Issue number6
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

MicroRNAs
NAD
Obesity
Liver
Nicotinamide Mononucleotide
Sterol Regulatory Element Binding Protein 1
Obese Mice
Glucose Intolerance
Metabolic Diseases
3' Untranslated Regions
Acetylation
Knockout Mice
Type 2 Diabetes Mellitus
Biological Availability
Down-Regulation
Binding Sites
Diet
Inflammation
Messenger RNA

Keywords

  • Deacetylation
  • Diabetes
  • MiR-34a
  • Resveratrol
  • Sirtuins
  • Steatosis

ASJC Scopus subject areas

  • Cell Biology
  • Aging

Cite this

Choi, S. E., Fu, T., Seok, S., Kim, D. H., Yu, E., Lee, K. W., ... Kemper, J. K. (2013). Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell, 12(6), 1062-1072. https://doi.org/10.1111/acel.12135

Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. / Choi, Sung E.; Fu, Ting; Seok, Sunmi; Kim, Dong Hyun; Yu, Eunkyung; Lee, Kwan Woo; Kang, Yup; Li, Xiaoling; Kemper, Byron; Kemper, Jongsook K.

In: Aging Cell, Vol. 12, No. 6, 12.2013, p. 1062-1072.

Research output: Contribution to journalArticle

Choi, SE, Fu, T, Seok, S, Kim, DH, Yu, E, Lee, KW, Kang, Y, Li, X, Kemper, B & Kemper, JK 2013, 'Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT', Aging Cell, vol. 12, no. 6, pp. 1062-1072. https://doi.org/10.1111/acel.12135
Choi, Sung E. ; Fu, Ting ; Seok, Sunmi ; Kim, Dong Hyun ; Yu, Eunkyung ; Lee, Kwan Woo ; Kang, Yup ; Li, Xiaoling ; Kemper, Byron ; Kemper, Jongsook K. / Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. In: Aging Cell. 2013 ; Vol. 12, No. 6. pp. 1062-1072.
@article{bcee3e7d1ea847ac82550bfae79b7a2f,
title = "Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT",
abstract = "SIRT1 is an NAD+-dependent deacetylase that is implicated in prevention of many age-related diseases including metabolic disorders. As SIRT1 deacetylase activity is dependent on NAD+ levels and the development of compounds that directly activate SIRT1 has been controversial, indirectly activating SIRT1 through enhancing NAD+ bioavailability has received increasing attention. NAD+ levels are reduced in obesity and the aged, but the underlying mechanisms remain unclear. We recently showed that hepatic microRNA-34a (miR-34a), which is elevated in obesity, directly targets and decreases SIRT1 expression. Here, we further show that miR-34a reduces NAD+ levels and SIRT1 activity by targeting NAMPT, the rate-limiting enzyme for NAD+ biosynthesis. A functional binding site for miR-34a is present in the 3′ UTR of NAMPT mRNA. Hepatic overexpression of miR-34a reduced NAMPT/NAD+ levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC-1α, SREBP-1c, FXR, and NF-κB, and resulted in obesity-mimetic outcomes. The decreased NAMPT/NAD+ levels were independent of miR-34a effects on SIRT1 levels as they were also observed in SIRT1 liver-specific knockout mice. Further, the miR-34a-mediated decreases were reversed by treatment with the NAD+ intermediate, nicotinamide mononucleotide. Conversely, antagonism of miR-34a in diet-induced obese mice restored NAMPT/NAD+ levels and alleviated steatosis, inflammation, and glucose intolerance. Anti-miR-34a-mediated increases in NAD+ levels were attenuated when NAMPT was downregulated. Our findings reveal a novel function of miR-34a in reducing both SIRT1 expression and activity in obesity. The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.",
keywords = "Deacetylation, Diabetes, MiR-34a, Resveratrol, Sirtuins, Steatosis",
author = "Choi, {Sung E.} and Ting Fu and Sunmi Seok and Kim, {Dong Hyun} and Eunkyung Yu and Lee, {Kwan Woo} and Yup Kang and Xiaoling Li and Byron Kemper and Kemper, {Jongsook K.}",
year = "2013",
month = "12",
doi = "10.1111/acel.12135",
language = "English (US)",
volume = "12",
pages = "1062--1072",
journal = "Aging Cell",
issn = "1474-9718",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT

AU - Choi, Sung E.

AU - Fu, Ting

AU - Seok, Sunmi

AU - Kim, Dong Hyun

AU - Yu, Eunkyung

AU - Lee, Kwan Woo

AU - Kang, Yup

AU - Li, Xiaoling

AU - Kemper, Byron

AU - Kemper, Jongsook K.

PY - 2013/12

Y1 - 2013/12

N2 - SIRT1 is an NAD+-dependent deacetylase that is implicated in prevention of many age-related diseases including metabolic disorders. As SIRT1 deacetylase activity is dependent on NAD+ levels and the development of compounds that directly activate SIRT1 has been controversial, indirectly activating SIRT1 through enhancing NAD+ bioavailability has received increasing attention. NAD+ levels are reduced in obesity and the aged, but the underlying mechanisms remain unclear. We recently showed that hepatic microRNA-34a (miR-34a), which is elevated in obesity, directly targets and decreases SIRT1 expression. Here, we further show that miR-34a reduces NAD+ levels and SIRT1 activity by targeting NAMPT, the rate-limiting enzyme for NAD+ biosynthesis. A functional binding site for miR-34a is present in the 3′ UTR of NAMPT mRNA. Hepatic overexpression of miR-34a reduced NAMPT/NAD+ levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC-1α, SREBP-1c, FXR, and NF-κB, and resulted in obesity-mimetic outcomes. The decreased NAMPT/NAD+ levels were independent of miR-34a effects on SIRT1 levels as they were also observed in SIRT1 liver-specific knockout mice. Further, the miR-34a-mediated decreases were reversed by treatment with the NAD+ intermediate, nicotinamide mononucleotide. Conversely, antagonism of miR-34a in diet-induced obese mice restored NAMPT/NAD+ levels and alleviated steatosis, inflammation, and glucose intolerance. Anti-miR-34a-mediated increases in NAD+ levels were attenuated when NAMPT was downregulated. Our findings reveal a novel function of miR-34a in reducing both SIRT1 expression and activity in obesity. The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.

AB - SIRT1 is an NAD+-dependent deacetylase that is implicated in prevention of many age-related diseases including metabolic disorders. As SIRT1 deacetylase activity is dependent on NAD+ levels and the development of compounds that directly activate SIRT1 has been controversial, indirectly activating SIRT1 through enhancing NAD+ bioavailability has received increasing attention. NAD+ levels are reduced in obesity and the aged, but the underlying mechanisms remain unclear. We recently showed that hepatic microRNA-34a (miR-34a), which is elevated in obesity, directly targets and decreases SIRT1 expression. Here, we further show that miR-34a reduces NAD+ levels and SIRT1 activity by targeting NAMPT, the rate-limiting enzyme for NAD+ biosynthesis. A functional binding site for miR-34a is present in the 3′ UTR of NAMPT mRNA. Hepatic overexpression of miR-34a reduced NAMPT/NAD+ levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC-1α, SREBP-1c, FXR, and NF-κB, and resulted in obesity-mimetic outcomes. The decreased NAMPT/NAD+ levels were independent of miR-34a effects on SIRT1 levels as they were also observed in SIRT1 liver-specific knockout mice. Further, the miR-34a-mediated decreases were reversed by treatment with the NAD+ intermediate, nicotinamide mononucleotide. Conversely, antagonism of miR-34a in diet-induced obese mice restored NAMPT/NAD+ levels and alleviated steatosis, inflammation, and glucose intolerance. Anti-miR-34a-mediated increases in NAD+ levels were attenuated when NAMPT was downregulated. Our findings reveal a novel function of miR-34a in reducing both SIRT1 expression and activity in obesity. The miR-34a/NAMPT axis presents a potential target for treating obesity- and aging-related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.

KW - Deacetylation

KW - Diabetes

KW - MiR-34a

KW - Resveratrol

KW - Sirtuins

KW - Steatosis

UR - http://www.scopus.com/inward/record.url?scp=84888131014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888131014&partnerID=8YFLogxK

U2 - 10.1111/acel.12135

DO - 10.1111/acel.12135

M3 - Article

C2 - 23834033

AN - SCOPUS:84888131014

VL - 12

SP - 1062

EP - 1072

JO - Aging Cell

JF - Aging Cell

SN - 1474-9718

IS - 6

ER -